Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer | Zendy

Obajdin J. | Zendy; Davies D. M. | Zendy; Maher J. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer

Author(s) -

Obajdin J.,

Davies D. M.,

Maher J.

Publication year - 2020

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/cei.13478

Subject(s) - nkg2d , chimeric antigen receptor , biology , immunotherapy , immunology , receptor , immune system , nk 92 , cancer research , innate immune system , lymphokine activated killer cell , cancer immunotherapy , natural killer cell , cancer cell , cancer , interleukin 21 , t cell , cytotoxic t cell , in vitro , biochemistry , genetics

Natural killer (NK) cells are innate immune effectors which play a crucial role in recognising and eliminating virally infected and cancerous cells. This article reviews strategies used to engineer chimeric antigen receptors whereby specificity is conferred by activating NK cell receptors targeting ligands commonly upregulated on cancer cells. These CARs are expressed in T cells or NK cells for use in adoptive immunotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research